Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3279-3287

  Sonneveld, Pieter ^a   Goldschmidt, Hartmut ^c   Rosiñol, Laura ^d   Bladé, Joan ^d   Lahuerta, Juan José ^e   Cavo, Michele ^f   Tacchetti, Paola ^f   Zamagni, Elena ^f   Attal, Michel ^g   Lokhorst, Henk M ^b   Desai, Avinash ⁱ   Cakana, Andrew ^k   Liu, Kevin ⁱ   Van De Velde, Helgi ^k   Esseltine, Dixie Lee ^j   Moreau, Philippe ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g CHU PURPAN   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j MILLENNIUM PHARMACEUTICALS INC   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; META ANALYSIS; MOTOR NEUROPATHY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; AUTOTRANSPLANTATION; CANCER STAGING; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DEXAMETHASONE; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84891651595     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4626     Document Type: Article

References (39)

1. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521-2526, 2008
2. Brenner H, Gondos A, Pulte D: Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94:270-275, 2009
3. Kastritis E, Zervas K, Symeonidis A, et al: Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:1152-1157, 2009
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
5. Anderson KC, Alsina M, Bensinger W, et al: Multiple myeloma. J Natl Compr Canc Netw 9:1146-1183, 2011
6. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364:1046-1060, 2011
7. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
8. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936, 2006
9. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristinedoxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39, 2005
10. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629, 2010
11. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946-2955, 2012
12. Ludwig H, Avet-Loiseau H, Bladé J, et al: European perspective on multiple myeloma treatment strategies: Update following recent congresses. Oncologist 17:592-606, 2012
13. Cavo M, Rajkumar SV, Palumbo A, et al: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:6063-6073, 2011
14. Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 114:3139-3146, 2009
15. Martinez-Lopez J, Blade J, Mateos MV, et al: Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529-534, 2011
16. Moreau P, Attal M, Pé gourié B, et al: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 117:3041-3044, 2011
17. van de Velde HJ, Liu X, Chen G, et al: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92:1399-1406, 2007
18. Rosiñol L, Oriol A, Teruel AI, et al: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase III PETHEMA/GEM study. Blood 120:1589-1596, 2012
19. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 376:2075-2085, 2010
20. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
21. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
22. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
23. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
24. Neben K, Lokhorst HM, Jauch A, et al: Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940-948, 2012
25. Cavo M, Sonneveld P, Moreau P, et al: Impact of bortezomib incorporated into autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: An integrated analysis of 1894 patients enrolled in four European phase 3 studies. Blood 120:749, 2012 (suppl; abstr 749)
26. Avet-Loiseau H, Leleu X, Roussel M, et al: Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630-4634, 2010
27. Anderson KC: The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445-452, 2012
28. Lahuerta JJ, Mateos MV, Martínez-López J, et al: Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26:5775-5782, 2008
29. Ludwig H, Viterbo L, Greil R, et al: Phase II study of bortezomib, thalidomide, and dexamethasone -/- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): Safety and activity including evaluation of MRD. Haematologica 95:149-150, 2010 (suppl; abstr 0371)
30. Kumar S, Flinn I, Richardson PG, et al: Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib,dexamethasone,cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375-4382, 2012
31. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686, 2010
32. Moreau P, Avet-Loiseau H, Facon T, et al: Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752-5758, 2011
33. Usmani SZ, Crowley J, Hoering A, et al: Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: Are patients now being cured? Leukemia 27:226-232, 2013
34. Bringhen S, Larocca A, Rossi D, et al: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:4745-4753, 2010
35. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440, 2011
36. Jakubowiak AJ, Dytfeld D, Griffith KA, et al: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120:1801-1809, 2012
37. Mikhael J, Reeder CB, Libby EN, et al: A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. J Clin Oncol 30:512s, 2012 (suppl; abstr 8010)
38. Sonneveld P, Hacker E, Zweegman S, et al: Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM): A trial of the European Myeloma Network EMN. Blood 118:290, 2011 (suppl; abstr 633)
39. Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120:9-19, 2012